Way overbought, do your research about the FDA clinical hold on Arikace
Most new investors probably don't even know that a clinical hold was placed on Arikace by the FDA in CF, it was only lifted last year in a select group of patients. Only NTM study is being clinically tried in US. CF is UK and Canada.
Overbought? For the shareholders who have been here awhile, they realize that there are only so many shares available from approximately 150 shareholders. Is this deja vu? With the institutions, hedgies, and other money managers having a large percentage, are they going to sell now or will they wait till June or thereafter? So, who is left to sell? Do they want to miss a possible runup in price, or do they want to capture their gain now? Are there new buyers trying to get in with small lot purchases or will they get in with larger shares at any price that they believe is attractive to them?Where can this share price go to?
Sorry medtrust, you're wrong. Clinical hold was lifted across the board and FDA required a dog trial. The trial came back with positive results, so basically all FDA objections have been met. No need for CF trial here, when a 300 member trial is being conducted internationally.